MyFinsight

HomeBlogAboutContact

MyFinsight

Making company financials insightful for everyone

Quick Links

  • About
  • Blog
  • Contact

Follow Us

  • X.com
  • Thread
  • Instagram

© 2026 MyFinsight. All rights reserved.

|||

For the year ending 2025-12-31, PBYI had -$39,584K decrease in cash & cash equivalents over the period. $41,731K in free cash flow.

Cash Flow Overview

Change in Cash
-$39,584K
Free Cash flow
$41,731K
Unit: Thousand (K) dollars
Positive Cash Flow Breakdown
    • Maturity of available-for-sale s...
    • Net income
    • Accrued expenses and other
    • Others
Negative Cash Flow Breakdown
    • Purchase of available-for-sale s...
    • Payment of debt
    • Accounts receivable, net
    • Others

Cash Flow
2025-12-31
Net income
31,111
Depreciation and amortization
10,938
Stock-based compensation
6,944
Deferred income taxes
3,245
Provision for credit loss recovery
-362
Loss on disposal of property and equipment
-4
Loss on impairment of asset
0
Accounts receivable, net
21,281
Inventory, net
-3,209
Prepaid expenses and other
325
Other current assets
165
Accounts payable
-453
Operating lease assets and liabilities, net
1,805
Accrued expenses and other
13,154
Post-marketing commitment liability
-2,412
Net cash provided by operating activities
41,802
Purchase of property and equipment
71
Purchase of available-for-sale securities
108,141
Maturity of available-for-sale securities
72,024
Purchase of intangible assets
0
Net cash used in investing activities
-36,188
Net proceeds from shares issued under employee stock plans
130
Payment of debt
44,440
Payment of exit costs
888
Net cash used in financing activities
-45,198
Net (decrease) increase in cash, cash equivalents and restricted cash
-39,584
Cash, cash equivalents and restricted cash, beginning of period
71,310
Cash, cash equivalents and restricted cash, end of period
31,726
Unit: Thousand (K) dollars (except for numbers of shares and EPS).

Time Plot

Show the time plot by selecting a row from the table.

Cash Flow

Net income$31,111K Accrued expenses andother$13,154K Depreciation andamortization$10,938K Stock-based compensation$6,944K Deferred income taxes$3,245K Inventory, net-$3,209K Loss on disposal ofproperty and equipment-$4K Net cash provided byoperating activities$41,802K Canceled cashflow$26,803K Net (decrease)increase in cash, cash...-$39,584K Canceled cashflow$41,802K Net proceeds fromshares issued under...$130K Maturity ofavailable-for-sale securities$72,024K Accounts receivable, net$21,281K Post-marketing commitmentliability-$2,412K Operating lease assets andliabilities, net$1,805K Accounts payable-$453K Provision for credit lossrecovery-$362K Prepaid expenses andother$325K Other current assets$165K Net cash used infinancing activities-$45,198K Canceled cashflow$130K Net cash used ininvesting activities-$36,188K Canceled cashflow$72,024K Payment of debt$44,440K Payment of exit costs$888K Purchase ofavailable-for-sale securities$108,141K Purchase of property andequipment$71K

PUMA BIOTECHNOLOGY, INC. (PBYI)

PUMA BIOTECHNOLOGY, INC. (PBYI)